Company: LBRX
Filing Date: 2025-07-23
Form Type: DRS/A
Source: 0000950123-25-006557
Chunk: 195

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-07-23
Form: DRS/A
Chunk 195
---
p=0.0214) for the 50 mg, 75 mg, and 100 mg dose cohorts, respectively, compared to a responder rate of 18.3% for the placebo cohort. We also assessed response to treatment with LB-102using PANSS subscales for positive and negative symptoms, respectively. Looking specifically at positive symptom response, we observed a 4.8-pointdecrease (p=0.0051), 4.9-pointdecrease (p=0.0039), and 5.3-pointdecrease (p=0.0120) in the PANSS subscale for the 50 mg, 75 mg, and 100 mg dose cohorts, respectively, compared to a 3.1-pointdecrease in the placebo cohort. When looking at the negative symptom PANSS subscale, we observed a 2.2-pointdecrease (p=0.0116), 1.7-pointdecrease (p=0.1633), and 1.8-pointdecrease (p=0.2632) in the 50 mg, 75 mg, and 100 mg dose cohorts, respectively, compared to a 1.1-pointdecrease in the placebo cohort. LS Mean change in PANSS score from baseline to Week 4 in positive subscale 138

LS Mean change in PANSS score from baseline to Week 4 in negative subscale

We also conducted an exploratory post-hoc analysis of our Phase 2 data on the treatment effect in
patients with negative symptoms at baseline (i.e., those patients with a PANSS Negative Subscore greater than or equal to 24). In patients with negative symptoms at baseline, the LS Mean change in negative symptom scores at Week 4 was -1.6 (placebo), -3.4 (50 mg, Δ -1.7, p=0.0045 versus placebo; effect size=0.67), -2.6 (75
mg, Δ -1.00, p=0.1501, effect size=0.34), and -3.3 (100 mg, Δ -1.70, p=0.0658, effect size=0.60). Across all analyses,
the effect on negative symptoms was seen as early as week 1, which continued through Week 4.

Using the
CGI-S scale, participants in all three dose cohorts demonstrated an improvement in total scores from baseline to Week 4. We